ABBOTT HEALTHCARE PRODUCTS LTD
Get an alert when ABBOTT HEALTHCARE PRODUCTS LTD files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2026-11-30 (in 6mo)
Last made up 2025-11-16
Watchouts
None on the register
Cash
—
Latest balance sheet
Net assets
£77M
+24.7% vs 2023
Employees
2
-71.4% vs 2023
Profit before tax
£18M
+27.4% vs 2023
Name history
Renamed 2 times since incorporation
- ABBOTT HEALTHCARE PRODUCTS LTD 2010-02-17 → present
- SOLVAY HEALTHCARE LIMITED 1995-06-12 → 2010-02-17
- DUPHAR LABORATORIES LIMITED 1969-03-05 → 1995-06-12
Net assets
2-year trend · vs Consumer Discretionary median
Accounts
2-year trend · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Turnover | £2,291,000 | £1,221,000 | |
| Operating profit | £50,000 | -£139,000 | |
| Profit before tax | £13,794,000 | £17,567,000 | |
| Net profit | £11,969,000 | £15,345,000 | |
| Cash | — | — | |
| Total assets less current liabilities | £62,062,000 | £77,407,000 | |
| Net assets | £62,062,000 | £77,407,000 | |
| Equity | £62,062,000 | £77,407,000 | |
| Average employees | 7 | 2 | |
| Wages | £1,476,000 | £979,000 |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating margin | 2.2% | -11.4% | |
| Net margin | 522.4% | 1256.8% | |
| Return on capital employed | 0.1% | -0.2% | |
| Current ratio | 5.85x | 5.08x | |
| Interest cover | 1.72x | — |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- Ernst & Young, Chartered Accountants
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The Company generated a net profit of £15,345,000 (2023: net profit £11,969,000), has net assets of £77,407,000 (2023: net assets of £62,062,000) and current assets of the Company exceeded its current liabilities by £64,353,000 (2023: £49,008,000). Trading profits are expected to continue in the foreseeable future. Therefore, after making enquiries, the Directors have a reasonable expectation that the Company will continue in operational existence for a period of twelve months from the date of approval of these financial statements. Accordingly, the Directors continue to adopt the going concern basis of accounting in preparing the annual report and financial statements.”
Group structure
- ABBOTT HEALTHCARE PRODUCTS LTD · parent
- British Colloids Limited 100%
Significant events
- “There were no significant events between the Balance Sheet date and the date of signing of the financial statements, affecting the Company, which require disclosure.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
4 active · 33 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| GOGAY, Kevan | Secretary | 2015-02-13 | — | — |
| CAMPBELL, Ross Iain | Director | 2025-04-25 | Apr 1976 | British |
| CLAYTON, Michael Robert Kendall | Director | 2020-03-23 | Apr 1974 | British |
| WENNER, James Russell | Director | 2025-12-10 | Sep 1967 | American |
Show 33 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| BOOTE, Michael George Ernest | Secretary | — | 1996-09-30 |
| CHAPMAN, Michael James | Secretary | 1996-10-01 | 1998-12-31 |
| DAWES, Melvin John | Secretary | 1999-01-01 | 2001-02-23 |
| ABOGADO NOMINEES LIMITED | Corporate Secretary | 2010-02-15 | 2015-02-13 |
| SOLVAY UK HOLDING COMPANY LIMITED | Corporate Secretary | 2001-02-23 | 2010-02-15 |
| BARRACLOUGH, Richard Alan | Director | 1996-09-03 | 1999-09-30 |
| BOOTE, Michael George Ernest | Director | — | 1996-09-03 |
| BROECKS, Bert Christian | Director | 2003-06-16 | 2006-12-12 |
| BROENS, Daniel | Director | 2001-03-05 | 2006-12-12 |
| DAVIES, Alison Elizabeth | Director | 2023-10-15 | 2025-12-10 |
| DE LAVENNE DE LA MONTOISE, Bertrand | Director | 2013-07-01 | 2014-12-12 |
| DE SLOOVER, Christian, Dr | Director | 1997-10-01 | 1999-06-30 |
| DEE, Thomas Joseph | Director | 2010-02-15 | 2013-09-30 |
| DUQUENNE, Thierry Amaury Adrien Marie | Director | 2006-12-12 | 2008-01-01 |
| ERNST, Jurgen | Director | 1997-10-01 | 2005-01-01 |
| FREYMAN, Thomas Craig | Director | 2010-02-15 | 2015-12-15 |
| HALL, Gary James | Director | 2015-10-02 | 2018-09-27 |
| HARRIS, Neil | Director | 2018-08-31 | 2025-04-25 |
| HUDSON, Susan Michelle | Director | 2016-11-28 | 2018-08-31 |
| KOZMINA, Natalia Sergeyevna | Director | 2011-07-20 | 2013-05-31 |
| KRAMMER, Karen Ann | Director | 2020-03-01 | 2022-09-19 |
| MCCOY JR, John Arthur | Director | 2022-09-19 | 2023-10-15 |
| MOUNTRICHAS, Georgios | Director | 2018-09-27 | 2020-03-23 |
| PETER, John Beverly, Dr | Director | — | 2008-01-01 |
| SAKSIDA, Kristian Thomas Dominic | Director | 1999-09-30 | 2003-06-30 |
| SMITH, Michael James | Director | 2015-02-13 | 2015-10-02 |
| TRAVERSE, Bertrand | Director | 2007-04-20 | 2010-02-15 |
| VAN ROYE, Gerard Jean Marie | Director | 2008-01-01 | 2010-02-15 |
| WEIDAUER, Thomas Jurgen, Dr | Director | 2008-01-01 | 2011-03-15 |
| WEITEKAMPER, Frank | Director | 2010-02-15 | 2017-01-05 |
| WESSOLOWSKI, Jurgen | Director | 1999-07-19 | 2012-10-30 |
| WITTELAAR, Joseph | Director | — | 1999-04-16 |
| YOOR, Brian | Director | 2015-12-15 | 2020-02-29 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Abbott Laboratories | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2016-04-06 | Active |
| Abbott Laboratories Inc. | Corporate entity | Shares 75–100%, voting-rights-75-to-100-percent-as-trust | 2016-04-06 | Active |
Filing timeline
Last 20 of 189 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2025-12-15 | AP01 | officers | Appoint person director company with name date | |
| 2025-12-15 | TM01 | officers | Termination director company with name termination date | |
| 2025-11-21 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-09-08 | AA | accounts | Accounts with accounts type full | |
| 2025-05-01 | AP01 | officers | Appoint person director company with name date | |
| 2025-04-30 | TM01 | officers | Termination director company with name termination date | |
| 2024-11-20 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-07-22 | AA | accounts | Accounts with accounts type full | |
| 2024-04-03 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-10-25 | AP01 | officers | Appoint person director company with name date | |
| 2023-10-25 | TM01 | officers | Termination director company with name termination date | |
| 2023-08-24 | AA | accounts | Accounts with accounts type full | |
| 2023-03-22 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2022-09-27 | AP01 | officers | Appoint person director company with name date | |
| 2022-09-27 | TM01 | officers | Termination director company with name termination date | |
| 2022-08-09 | AA | accounts | Accounts with accounts type full | |
| 2022-03-24 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2021-10-07 | AA | accounts | Accounts with accounts type full | |
| 2021-03-24 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2020-10-07 | AA | accounts | Accounts with accounts type full |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 5
- Capital events
- 0
- Officers appointed
- 1
- Officers resigned
- 1
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31
-
Turnover
-46.7%
£2,291,000 £1,221,000
-
Cash
—
Not reported
-
Net assets
+24.7%
£62,062,000 £77,407,000
-
Employees
-71.4%
7 2
-
Operating profit
-378%
£50,000 -£139,000
-
Profit before tax
+27.4%
£13,794,000 £17,567,000
-
Wages
-33.7%
£1,476,000 £979,000
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers